These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 30221663)
1. Post‑transplant lymphoproliferative disorder in hematopoietic stem cell transplant patients: A single center retrospective study between 2005 and 2012. Marinho-Dias J; Lobo J; Henrique R; Baldaque I; Pinho-Vaz C; Regadas L; Branca R; Campilho F; Campos A; Medeiros R; Sousa H Mol Med Rep; 2018 Nov; 18(5):4650-4656. PubMed ID: 30221663 [TBL] [Abstract][Full Text] [Related]
2. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases]. Chen DB; Wang Y; Song QJ; Shen DH Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829 [TBL] [Abstract][Full Text] [Related]
4. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. Naik S; Riches M; Hari P; Kim S; Chen M; Bachier C; Shaughnessy P; Hill J; Ljungman P; Battiwalla M; Chhabra S; Daly A; Storek J; Ustun C; Diaz MA; Cerny J; Beitinjaneh A; Yared J; Brown V; Page K; Dahi PB; Ganguly S; Seo S; Chao N; Freytes CO; Saad A; Savani BN; Woo Ahn K; Boeckh M; Heslop HE; Lazarus HM; Auletta JJ; Kamble RT Transpl Infect Dis; 2019 Oct; 21(5):e13145. PubMed ID: 31301099 [TBL] [Abstract][Full Text] [Related]
5. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation. Kalra A; Roessner C; Jupp J; Williamson T; Tellier R; Chaudhry A; Khan F; Taparia M; Jimenez-Zepeda VH; Stewart DA; Daly A; Storek J Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29114932 [TBL] [Abstract][Full Text] [Related]
6. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Kuno M; Ito A; Maeshima AM; Taniguchi H; Tanaka T; Inamoto Y; Kurosawa S; Kim SW; Fukuda T Int J Hematol; 2020 Aug; 112(2):193-199. PubMed ID: 32472530 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. Gärtner BC; Schäfer H; Marggraff K; Eisele G; Schäfer M; Dilloo D; Roemer K; Laws HJ; Sester M; Sester U; Einsele H; Mueller-Lantzsch N J Clin Microbiol; 2002 Feb; 40(2):351-8. PubMed ID: 11825941 [TBL] [Abstract][Full Text] [Related]
8. Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult. Chen DB; Liu XY; Kong FZ; Jiang Q; Shen DH J Clin Pathol; 2021 Nov; 74(11):697-703. PubMed ID: 34011618 [TBL] [Abstract][Full Text] [Related]
9. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S; Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985 [TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation. Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566 [TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment. Overkamp M; Granai M; Bonzheim I; Steinhilber J; Schittenhelm J; Bethge W; Quintanilla-Martinez L; Fend F; Federmann B Virchows Arch; 2021 Jun; 478(6):1135-1148. PubMed ID: 33324999 [TBL] [Abstract][Full Text] [Related]
12. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation. Kim BK; Kang HJ; Hong KT; An HY; Choi JY; Lee JS; Park SS; Shin HY Transpl Infect Dis; 2019 Dec; 21(6):e13182. PubMed ID: 31556214 [TBL] [Abstract][Full Text] [Related]
14. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation. Chen DB; Song QJ; Chen YX; Chen YH; Shen DH Int J Hematol; 2013 Jan; 97(1):117-24. PubMed ID: 23255160 [TBL] [Abstract][Full Text] [Related]
16. [The diagnostic value of whole blood Epstein-Barr virus DNA load in lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation]. Niu YY; Dong YJ; Yin Y; Xu WL; Liang ZY; Wang Q; Li Y; Liu W; Ou JP; Ren HY Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):904-910. PubMed ID: 35045651 [No Abstract] [Full Text] [Related]